Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib and Azacitidine in IDH1-Mutated AML
NCT07304011Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olutasidenib in acute myeloid leukemia (AML), sponsored by University of California, Davis. Started Dec 2025; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07304011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304011.